NASDAQ
3.85USD
-0.34 (-8.11%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
223M
P/E
—
EPS
—
Beta
0.42
52W range
2.96-40.37
Day range
3.80–4.66
Open
4.05
Prev close
4.19
Volume
7.2M
Avg volume
2.5M
Dividend
0.00
IPO
2007-02-13
https://www.globenewswire.com/news-release/2026/07/30/3335720/32716/en/CAPR-Alert-Capricor-Therapeutics-Inc-NASDAQ-CAPR-Investors-Urged-to-Contact-Hagens-Berman-Investigation-Opened-Following-Massive-Stock-Crash.html · 7/30/2026-1.00
https://www.proactiveinvestors.com/companies/news/1096081 · 7/27/2026-1.00
https://www.fool.com/coverage/filings/2026/07/25/this-capricor-insider-sold-24-000-shares-before-the-drop-with-a-new-catalyst-on-the-way-is-it-time-to-buy-again/ · 7/25/2026+0.00
https://www.newsfilecorp.com/release/302259/Caprock-Announces-Closing-of-Private-Placement · 6/19/2026+0.40
https://www.newsfilecorp.com/release/301952/Early-Warning-Press-Release-Frank-Guillemette-Announces-Completion-of-Acquisition-of-Common-Shares-of-Caprock-Mining-Corp. · 6/17/2026
https://www.newsfilecorp.com/release/301306/Caprock-Announces-Consistent-HighGrade-Intercepts-from-the-Final-Three-Deep-Drill-Holes-at-Destiny-Including-8.32-gt-Au-over-2.6m · 6/12/2026+0.80
https://seekingalpha.com/article/4911297-capricor-stock-rate-it-a-buy-after-stress-testing-the-sell-thesis · 6/3/2026+0.60
https://www.newsfilecorp.com/release/298748/Early-Warning-Press-Release-Frank-Guillemette-Announces-Completion-of-Acquisition-of-Common-Shares-of-Caprock-Mining-Corp · 5/25/2026+0.30
https://www.reuters.com/business/energy/uks-capricorn-energy-says-unit-saudis-cafani-must-make-offer-by-may-6-2026-04-08/ · 4/8/2026+0.30
https://www.benzinga.com/trading-ideas/movers/26/03/51248600/capricor-therapeutics-stock-slides-as-q4-earnings-miss-estimates · 3/13/2026-0.60
https://www.defenseworld.net/2025/12/31/capricor-therapeutics-nasdaqcapr-versus-glucose-health-otcmktsgluc-head-to-head-survey.html · 12/31/2025+0.00
https://seekingalpha.com/article/4851011-capricor-maintaining-hold-rating-on-randomized-phase-3-hope-3-trial-win-with-deramiocel · 12/7/2025+0.40
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
